Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $90
Benzinga Newsdesk 6 hours ago
Analyst RatingsNewsPrice Target
Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $88 to $90.
Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $88 to $90.